文献速递消化内镜消化道肿瘤与早癌

两代结肠镜改进对腺瘤漏诊率的影响:前瞻性随机多中心串联研究结果

Impact of 2 generational improvements in colonoscopes on adenoma miss rates: results of a prospective randomized multicenter tandem study.
PubMed 文献 · Gastrointest Endosc · 2018-02-04

该前瞻性随机多中心串联研究比较了最新一代结肠镜(奥林巴斯 Exera III,190-C)与上一代(奥林巴斯 160/5-C)对腺瘤漏诊率的影响,共纳入 856 例结直肠肿瘤风险增高患者。结果显示,190-C 组首次检查腺瘤漏诊率 16.6%(95%CI 13.0%-20.1%),低于 160/5-C 组的 30.2%(95%CI 25.9%-34.6%)(P < .001);腺瘤检出率分别为 43.8% 与 36.5%(P = .030)。

要点

  • 190-C 组首次检查腺瘤漏诊率 16.6%,低于 160/5-C 组的 30.2%(P < .001)。
  • 190-C 组首次结肠镜腺瘤检出率 43.8%,高于 160/5-C 组的 36.5%(P = .030)。
  • 作者认为需经过两代器械改进才能观察到对腺瘤漏诊率的影响。

核心结论

  • 该随机串联试验显示,与 160/5 系列相比,较新的 190 结肠镜腺瘤漏诊率更低、腺瘤检出率更高。
  • 作者认为需要多项改进(如经过两代器械改进)才能观察到对腺瘤漏诊率的影响。

研究设计与样本

  • 前瞻性多中心随机串联研究,随机分配结肠镜检查顺序,涉及 2 名不同的检查者。
  • 比较同一公司最新一代结肠镜(奥林巴斯 Exera III,190-C)与上一代(奥林巴斯 160/5-C)。
  • 纳入结直肠肿瘤风险增高的患者(粪便隐血试验阳性、结直肠癌/腺瘤个人史或家族史、直肠出血、近期排便习惯改变)。
  • 共纳入 856 例患者(48.8% 男性;平均年龄 58.3 岁),其中结直肠肿瘤个人史 41%、家族史 38%、直肠出血 19% 及其他指征。
  • 主要结局为 190(190-C)结肠镜与 160/5 结肠镜(160/5-C)相比的腺瘤漏诊率。

主要发现

  • 190-C 首先检查组 429 例患者中,16.6%(95%CI 13.0%-20.1%)在首次检查中至少漏诊 1 个腺瘤。
  • 160/5-C 首先检查组中,30.2%(95%CI 25.9%-34.6%)在首次检查中至少漏诊 1 个腺瘤(P < .001)。
  • 首次结肠镜检查腺瘤检出率 190-C 组为 43.8%,160/5-C 组为 36.5%(P = .030)。

关键数值与推荐

  • 190-C 组首次检查腺瘤漏诊率 16.6%(95%CI 13.0%-20.1%)vs 160/5-C 组 30.2%(95%CI 25.9%-34.6%)(P < .001)。
  • 190-C 组首次结肠镜腺瘤检出率 43.8% vs 160/5-C 组 36.5%(P = .030)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Numerous randomized studies have shown that changing certain features of colonoscopes, usually incorporated when switching from one endoscope generation to the next, mostly do not increase adenoma yield. There is, however, indirect evidence that it may be necessary to skip one instrument generation (ie, changing from one generation to the next but one) to achieve this effect. METHODS: We compared the latest-generation colonoscopes from one company (Olympus Exera III, 190-C) with the next to last one (Olympus 160/5-C) in a prospective multicenter study randomized for the order of colonoscopes in a tandem fashion, involving 2 different examiners. Patients with increased risk for colorectal neoplasia undergoing colonoscopy (positive fecal occult blood test, personal/familial history of colorectal cancer/adenoma, rectal bleeding, recent change in bowel movements) were included. The primary outcome was the adenoma miss rate with the 190 (190-C) colonoscope in comparison with the 160/5 colonoscope (160/5-C). RESULTS: A total of 856 patients (48.8% male; mean age, 58.3 years) with a personal (41%) or family (38%) history of colorectal neoplasia, rectal bleeding (19%), and other indications were included. Of the 429 patients in the 190-C first group, 16.6% (95% confidence interval [CI], 13.0%-20.1%) had at least one adenoma missed during the first procedure, compared with 30.2% (95% CI, 25.9%-34.6%) in the group with 160/5-C first (P < .001). Similarly, the adenoma detection rate during the first colonoscopy was 43.8% versus 36.5% (P = .030) for 190-C versus 160/5-C, respectively. CONCLUSIONS: This randomized tandem trial showed lower adenoma miss rates and higher adenoma detection rates for the newer 190 colonoscopes compared with the 160/5 series. These results suggest that it takes multiple improvements, such as those implemented over 2 instrument generations, before an effect on adenoma (miss) rate can be observed. (Study registration number: ISRCTN 2010-A01256-33.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Pioche M, Denis A, Allescher HD, et al. Impact of 2 generational improvements in colonoscopes on adenoma miss rates: results of a prospective randomized multicenter tandem study. Gastrointest Endosc. 2018. PMID: 29410020. doi:10.1016/j.gie.2018.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。